In the context of the discussion, share price is irrelevant when comparing a 50 million fully diluted company with a 200 million share with 500 million share for the purpose of demonstrating that the 50 million share company will never reach $10 a share because the other two aren't there even though the other two are in very high development cost areas for biologicals or the drugs in development have one tenth the market potentia, among other major factors.
SP is only useful in determining and comparing caps within the larger context of valuations.
News 
Market Data 
Discover 
AI
